GCM
CRDF icon

Graham Capital Management’s Cardiff Oncology CRDF Stock Holding History

Graham Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,718
Closed -$59K – 1310
2025
Q2 		$59K Buy
+18,718
New +$57.1K ﹤0.01% 1237
2024
Q3 		– Sell
-41,922
Closed -$93.1K – 1135
2024
Q2 		$93.1K Buy
+41,922
New +$158K ﹤0.01% 953

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Graham Capital Management's CRDF Position: Q3 2025 in Review

Graham Capital Management sold out of Cardiff Oncology (CRDF) in Q3 2025, closing a stake of 18,718 shares — an estimated $59K sold.

Graham Capital Management first reported a position in CRDF in Q2 2024 and held it in 2 quarters. The position peaked at $93.1K in Q2 2024. 112 funds tracked by Wall St. Rank hold CRDF as of Q3 2025.

  • Graham Capital Management reported no remaining Cardiff Oncology position as of Q3 2025 after selling out during the quarter.
  • Graham Capital Management sold 18,718 Cardiff Oncology shares in Q3 2025, an estimated $59K.
  • Graham Capital Management first reported a position in Cardiff Oncology in Q2 2024 and held it in 2 quarters.
  • Graham Capital Management's Cardiff Oncology position peaked at $93.1K in Q2 2024.
  • 112 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.